Lignosus Rhinoceros TM02® as a Complementary Therapy for Uncontrolled Asthma
Status:
COMPLETED
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if TM02® works to treat partially controlled or uncontrolled asthma in adults. It will also learn about the efficacy and safety of TM02®.
The main questions it aims to answer are:
Does TM02® causes bronchodilation (to what extent), improves asthma control, and reduces airway inflammation and blood eosinophils and serum immunoglobulin E levels.
Participants will:
Take TM02® every day for 90 days. Visit the clinic once every 30 days for checkups, tests and to fill up questionnaires.
Keep a diary of their symptoms and the number of times they use a rescue inhaler.